Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medarex Studying Ipilimumab As First-Line Treatment For Metastatic Melanoma

This article was originally published in The Pink Sheet Daily

Executive Summary

The registrational trial will compare patients treated with ipilimumab and decarbazine with decarbazine alone.

You may also be interested in...



Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure

Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.

Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure

Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.

Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)

Pfizer VP and Oncology Therapeutic Head Charles Baum talks to “The Pink Sheet” DAILY in an exclusive interview about the pharma giant’s increasing research emphasis in cancer drugs, and about pipeline developments, including axitinib in pancreatic cancer and a CTLA4 inhibitor, tremelimumab, for melanoma.

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel